

OPEN ACCESS

Lipid A-based affinity biosensor for screening anti-sepsis components from herbs

Jie YAO*¹, Yiguo CHEN*^{1,2}, Ning WANG*, Dongneng JIANG* and Jiang ZHENG*³

*Medical Research Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, People's Republic of China

Synopsis

LPS (lipopolysaccharide), an outer membrane component of Gram-negative bacteria, plays an important role in the pathogenesis of sepsis and lipid A is known to be essential for its toxicity. Therefore it could be an effective measure to prevent sepsis by neutralizing or destroying LPS. Numerous studies have indicated that many traditional Chinese medicines are natural antagonists of LPS *in vitro* and *in vivo*. The goal of this study is to develop a rapid method to screen anti-sepsis components from Chinese herbs by use of a direct lipid A-based affinity biosensor technology based on a resonant mirror. The detergent OG (*n*-octyl β -D-glucopyranoside) was immobilized on a planar non-derivatized cuvette which provided an alternative surface to bind the terminal hydrophilic group of lipid A. A total of 78 herbs were screened based on the affinity biosensor with a target of lipid A. The aqueous extract of PSA (*Paeonia suffruticosa* Andr) was found to possess the highest capability of binding lipid A. Therefore an aqueous extraction from this plant was investigated further by our affinity biosensor, polyamide chromatography and IEC-HPLC. Finally, we obtained a component (PSA-I-3) from *Paeonia suffruticosa* Andr that was evaluated with the affinity biosensor. We also studied the biological activities of PSA-I-3 against sepsis *in vitro* and *in vivo* to further confirm the component we screened with the biosensor. *In vitro*, we found that PSA-I-3 could decrease TNF α (tumour necrosis factor α) release from RAW264.7 cells induced by LPS in a dose-dependent manner. *In vivo*, it increased remarkably the survival of KM (KunMing) mice by challenging both lethal-dose LPS and heat-killed *Escherichia coli* compared with control groups. Our results suggest that the constructed affinity biosensor can successfully screen the anti-sepsis component from Chinese herbs.

Key words: affinity biosensor, Chinese herbs, lipid A, sepsis.

Cite this article as: Yao, J., Chen, Y., Wang, N., Jiang, D. and Zheng, J. (2014) Lipid A-based affinity biosensor for screening anti-sepsis components from herbs. Biosci. Rep. **34**(3), art:e00109.doi:10.1042/BSR20130103

INTRODUCTION

Sepsis is a complex syndrome that is defined as the presence of infection plus SIRS (systemic inflammatory response syndrome) [1]. In the USA, sepsis syndrome is responsible for a tenth of all deaths. The mortality rate for inpatients with sepsis is approximately 30–55% and higher for the elderly [2,3]. Moreover, the conditions of sepsis are worse in developing countries owing to poor healthcare and environment. Although Gram-negative bacteria are no longer the number one cause of sepsis in recent years, as people now pay more attention [4,5], infections still result in severe outcomes such as sepsis, severe sepsis and septic shock

in most of these critically ill populations who do not receive appropriate and timely therapy [6].

LPS (lipopolysaccharide) is an outer membrane component of Gram-negative bacteria and more than 2×10^6 LPS molecules comprise a polysaccharide part, O-antigen and core regions, and a lipid anchor, called lipid A, known to be essential for its toxicity [7]. Numerous studies have indicated that LPS triggers pathogenesis of sepsis by recognizing TLR4 (Toll-like receptor 4) and CD14 on the surface of cells; so an effective way to prevent sepsis could be by neutralizing LPS [8–12]. In recent years, many therapeutic strategies were taken against LPS including McAbs, polyclonal antibodies, leucocyte proteins (BPI), PMB (polymyxin B), mimic peptides, etc. [13–19]. Unfortunately, to

Abbreviations: CFU, colony-forming units; DMEM, Dulbecco's modified Eagle's medium; KM, KunMing; LAL, *Limulus* amoebocyte lysate; LB, Luria-Bertani; LPS, lipopolysaccharide; NS, normal saline; OG, *n*-octyl β -D-glucopyranoside; PMB, polymyxin B; PSA, *Paeonia suffruticosa* Andr; SIRS, systemic inflammatory response syndrome; SPF, specific pathogen free; TNF α , tumour necrosis factor α .

¹These authors contributed equally to this work.

²Present address: The Clinical Medical Laboratories of People's Hospital of Jiangxi Province, Nanchang, Jiangxi, People's Republic of China.

³To whom correspondence should be addressed (email zhengj@mail.tmmu.com.cn).

date, there is not yet a safe and effective agent to protect victims from sepsis caused by LPS.

In China, Chinese herbs have been used as drugs for critically ill patients for thousands of years. There is evidence that also suggests that many Chinese traditional herbs possess an anti-sepsis function [20]; however, traditional herbs are so complex that their clinical applications are restricted greatly. We have thus become interested in exploring a method with advantages of being sensitive, fast, accurate, label-free, simple and quantitative. In the present study, lipid A was immobilized on the OG (*n*-octyl β -D-glucopyranoside)-coated surface of a non-derivatized cuvette to construct an affinity biosensor developed to screen anti-sepsis herb technology in 2004. This identified some anti-sepsis fractions or monomers from *Radix Paeoniae Rubra*, *Scutellaria baicalensis* Georgi and *Terminaliachabula* Retz in the following years [21–23]. Herein, we found that 12 aqueous extractions from 78 Chinese herbs could bind greatly to lipid A which was immobilized on to a non-derivatized cuvette of the affinity biosensor and the non-tannin aqueous extraction from PSA (*Paeonia suffruticosa* Andr) possessed the highest lipid A-binding ability after consuming the indicated LPS concentration. Therefore an aqueous extraction from this plant was investigated further by an affinity biosensor, polyamide chromatography and IEC–HPLC. Finally, we obtained a fraction (PSA-I-3) from *Paeonia suffruticosa* Andr and investigated its anti-sepsis activities *in vitro* and *in vivo*.

MATERIALS AND METHODS

Reagents

LPS from *Escherichia coli* O111:B4 and lipid A from *Salmonella* Re 595 were obtained from Sigma Chemicals. Mouse TNF α (tumour necrosis factor α) ELISA kits were obtained from Bio-source International. The kinetic turbidimetric LAL (*Limulus* amoebocyte lysate) kit was obtained from Zhanjiang A & C Biological Ltd., and gelatine was purchased from Sino-pharm Chemical Reagent Co., LtdS.

Chinese herbs

Twelve Chinese herbs were identified in the Chongqing Academy of the Chinese Materia Medica (Chongqing, China) which were purchased from Sichuan Province.

Mice

Eighty KM (KunMing) mice (4–6 weeks old), with an equal number of males and females at random, were obtained from the Experimental Animal Center of Chongqing Medical University (Chongqing, China). The weight of the mice was 20 ± 2 g. The mice were housed in SPF (specific pathogen-free) conditions until use, and in agreement with principles stated in the Guide for the Care and Use of Laboratory Animals. National Research Council Publication, 1996 edition.

Table 1 Lipid A-binding activity of aqueous extracts bound to the indicated LPS concentration after removing tannins

Extract	Response unit (arc-sec)		
	50 ml (NS)	20 ng (LPS)	50 ng (LPS)
<i>Scutellaria baicalensis</i> Georgi	190	133	129
<i>Terminaliachabula</i> Retz	473	255	211
<i>Fructus crataegi</i>	580	348	227
<i>Biota orientalis</i>	638	573	215
<i>Rhizoma coptidis</i>	419	278	219
<i>Radix et Rhizoma Rhei</i>	810	589	564
Chinese White Olive	581	228	135
<i>Tripterygium Wilfordii</i>	427	368	298
<i>Radix Paeoniae Rubra</i>	511	469	244
<i>Radix Sanguisorbae</i>	626	555	369
<i>Caulis Sargentodoxae</i>	633	583	553
<i>Paeonia suffruticosa</i> Andr	952	702	654

Cell line and culture

The mouse macrophage cell line RAW264.7 was obtained from American Type Culture Collection (Manassas, VA), and was grown in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% (v/v) FBS (HyClone), 2 μ M glutamine, 100 units/ml penicillin and 100 μ g/ml streptomycin at 37°C in a humidified 5% (v/v) CO₂ incubator. In each experiment, 10⁶ cells/well were used.

Preparation of bacterial strains

E. coli (ATCC 25922) maintained in our laboratory were sub-cultured on the LB (Luria–Bertani) agar plate for 18 h, and then passaged into LB broth (containing 10 g tryptone, 10 g NaCl and 5 g yeast extract per litre) and cultivated aerobically in a 50 ml volume at 37°C in a heated, shaking environmental chamber for 18 h and transferred to 1000 ml of fresh LB broth for another 18 h. They were harvested by centrifugation. Finally, the bacteria were resuspended in sterile NS (normal saline) and killed at 100°C in hot water for 30 min.

Preparation of aqueous extracts of 12 Chinese herbs

Aqueous extracts of 12 Chinese herbs were prepared as described in [22]. Briefly, 2 g of 12 herbs were added to 10 ml distilled water after pulverization and heated in a water bath at 100°C for 1 h. The 12 aqueous extractions were centrifuged at 4°C at 5000 rev/min for 3 min and each supernatant was collected after filtration for the next assays.

Removing tannins from 12 Chinese herbs

The 12 supernatants as stated above were co-incubated with excessive gelatine (4%, w/v) at 50°C for 1 h. The supernatants, after centrifugation at 4°C, 10 000 rev/min for 5 min, were collected and stored at 4°C for the following assays.




Figure 1 Aqueous extracts from PSA and their lipid A-binding abilities
(a) Isolation with polyamide chromatography. Aqueous extract of PSA was passed over column chromatography with polyamide (80–100 mesh, 45 mm×250 mm), and eluted with distilled water, absolute ethanol and $\text{NH}_3\cdot\text{H}_2\text{O}$ (1%), respectively. We obtained together four fractions, named PSAI–IV. **(b)** Five microlitres of PSAI–IV ($10\ \mu\text{g}/\text{ml}$) were assayed for binding activity to lipid A. Lines I–IV represented their lipid A-binding abilities.

Consumption assays of the indicated LPS concentration

Approximately $50\ \mu\text{l}$ supernatants, after removing tannins, were co-incubated in the presence or absence of $50\ \mu\text{l}$ LPS (20, 50 ng/ml) at 30°C for 30 min. After centrifugation at 4°C , 5000 rev/min for 3 min the supernatants were collected and stored at 4°C for use in lipid A-binding assays.

Lipid A was immobilized on to the surface of a non-derivatized cuvette according to the manufacturer's instruction (Thermo Lab-system) as described in [22]. Briefly, 5 ml of 12 supernatants after consumption of the indicated LPS concentration was assayed for

its binding activity to lipid A as described in [22]. Data are shown in Table 1.

Isolation of lipid A-binding fractions from PSA

Approximately 1 kg PSA was boiled in distilled water at 80°C for 1 h via regurgitant extraction and tannins were removed by excessive gelatine (4%) at 50°C for 1 h before filtration. The filtrate was centrifuged at $4000g$ for 30 min and the supernatant was collected, which was passed over column chromatography with polyamide (80–100 mesh, $45\times 250\ \text{mm}$), eluted with




Figure 2 The elution from PSA-I via IEC-HPLC and their lipid A-binding abilities

(a) In order to investigate further the anti-LPS characteristics of PSA-I, we purified further the first fraction (PSA-I) via IEC-HPLC. To this end, the fraction (PSA-I) was injected on to an IEC-HPLC system (SPFF 90 μ m, GE Healthcare), eluted with acetic acid (pH 4.0), double-distilled water and $\text{NH}_3\cdot\text{H}_2\text{O}$ (1 %) adding ethanol (1 %), respectively. We obtained, in total, three HPLC fractions, named PSA1–3. (b) Five microlitres of PSA1–3 (10 μ g/ml) were assayed for binding activity to lipid A. Lines 1–3 represented their lipid A-binding abilities.

distilled water, absolute ethanol and $\text{NH}_3\cdot\text{H}_2\text{O}$ (1 %). The elution was collected and concentrated by rotary evaporation (BUCHI Rotavapor R205) to collectively obtain four fractions, named PSAI–IV. Briefly 5 μ l PSAI–IV (10 μ g/ml) was assayed for its binding activity to lipid A, as described in [22]. The results indicated that the first fraction (PSA-I) bound more markedly to lipid A than the others, and at more than 1800 arc-sec (Figure 1b).

In order to investigate the anti-LPS characteristics of PSA-I, we further purified the first fraction (PSA-I) via IEC-HPLC. To this end, the fraction (PSA-I) was injected on to the IEC-HPLC system (SPFF 90 μ m, GE Healthcare), eluted with acetic acid (pH 4.0), double-distilled water and $\text{NH}_3\cdot\text{H}_2\text{O}$ (1 %) adding ethanol (1 %, v/v), respectively, to obtain three HPLC fractions

(PSA1–3). Briefly 5 μ l of PSA1–3 (10 μ g/ml) was assayed for its binding activity to lipid A as described previously [22]. We found that the third fraction (PSA-I-3) bound markedly to lipid A at up to 550 arc-sec (Figure 2b).

LPS neutralization by PSA-I-3 *in vitro*

To determine whether PSA-I-3 could antagonize the bioactivity of LPS, we verified LPS neutralization by PSA-I-3 *in vitro* using the *Limulus* test, which is widely used to detect the concentration of microamounts of endotoxin. For this experiment, two concentrations of the PSA-I-3 (1 and 10 μ g/ml) were co-incubated in the presence or absence of LPS (10 ng) at 37 °C for 30 min;




Figure 3 Inhibition of TNF α release from LPS-stimulated RAW264.7 cells

For this experiment, 1×10^5 RAW264.7 cells ($200 \mu\text{l}$) were plated on to a 96-well microplate and cultured at 37°C in a humidified 5% CO_2 incubator for 4 h to subconfluency. The cells were pretreated with PSA-I-3 at the indicated dose (45, 90 and $180 \mu\text{g}/\text{ml}$) for 30 min followed by replacement with 0.5 ml serum-free DMEM, and then stimulated with and without LPS ($100 \mu\text{g}/\text{l}$) for 4 h. RAW264.7 cells were also treated with a positive control ($10 \mu\text{g}$ PMB + $100 \mu\text{g}/\text{l}$ LPS), and negative and blank control groups were $100 \mu\text{g}/\text{l}$ LPS and an equal volume of serum-free DMEM respectively. Supernatants were collected to test the TNF α level using mouse ELISA kits. The value of TNF α was expressed as mean (pg/ml) $\pm$ S.D. A P -value <0.05 (double-sided) was considered as significant, and a P -value <0.01 was considered as very significant. The test was carried out no less than three times.

the control experiments were as follows: positive control ($1 \mu\text{g}$ PMB + 10 ng LPS), negative control (10 ng LPS) and internal controls (sterile NS). Then $100 \mu\text{l}$ of each mixture was added to LAL reagent of an equal volume, and the kinetic turbidity was measured using an EDS-99 Tube Reader (Zhanjiang A&C Biological Ltd.).

Inhibition of TNF α release by RAW264.7 cells induced by LPS

For this experiment, 1×10^5 RAW264.7 cells ($200 \mu\text{l}$) were plated on to a 96-well microplate and cultured at 37°C in a humidified 5% CO_2 incubator for 4 h to subconfluency. The cells were pretreated with PSA-I-3 at the indicated dose (45, 90 and $180 \mu\text{g}/\text{ml}$) for 30 min, followed by replacement with 0.5 ml serum-free DMEM. Cells were then stimulated with and without LPS ($100 \mu\text{g}/\text{l}$) for 4 h. Positive control ($10 \mu\text{g}$ PMB + $100 \mu\text{g}/\text{l}$ LPS), negative controls and blank control groups were $100 \mu\text{g}/\text{l}$ LPS and an equal volume of serum-free DMEM, respectively. Supernatants were collected to test the TNF α level using mouse ELISA kits.

Protection of PSA-I-3 on mice challenged by LPS

A total of 40 mice (KM) were randomly divided into four groups (10 mice per group), mice (KM) were challenged with LPS ($18 \text{ mg}/\text{kg}$) via the tail vein. Subsequently, PMB ($2 \text{ mg}/\text{kg}$) and PSA-I-3 ($100 \text{ mg}/\text{kg}$) were injected as the positive control and treatment groups using identical procedures as stated above. PSA-I-3 ($100 \text{ mg}/\text{kg}$) alone was used as a blank control. The mice survival was assessed at 6, 12, 24, 36, 48, 60, 72, 96 and 108 h.

Protection of PSA-I-3 on mice challenged by heat-killed *E. coli*

A total of 40 mice (KM) were randomly divided into four groups (10 mice per group) and were injected via the tail vein as follows: heat-inactivated *E. coli* [6.0×10^9 CFU (colony-forming units)/kg] alone as the negative control, heat-inactivated *E. coli* (6.0×10^9 CFU/kg) adding dexamethasone ($5 \text{ mg}/\text{kg}$) as the positive control, and heat-inactivated *E. coli* (6.0×10^9 CFU/kg) and immediate subsequent injection of PSA-I-3 ($100 \text{ mg}/\text{kg}$) as the treatment group. PSA-I-3 ($100 \text{ mg}/\text{kg}$) alone was the blank

control. The general conditions and mice mortalities were assessed at 6, 12, 24, 36, 48, 60, 72, 96 and 108 h.

Statistical analysis

Statistical comparisons of the survival between the experimental and control groups were made using the χ^2 test, and others were conducted via independent samples using Student's *t* test with the SPSS 11.0 software package. $P < 0.05$ (double-sided) was considered as significant, and $P < 0.01$ was considered as very significant.

RESULTS

Aqueous extracts of 12 Chinese herbs (after removal of tannins) bound to the indicated LPS concentration

In previous experiments, we found that 12 out of the 78 herbs possess high lipid A-binding activities (more than 200 arc-sec) and the tannins have a great impact on binding between lipid A and Chinese herbs. Therefore we carried out an experiment to remove tannins from Chinese herbs, and then the 12 supernatants, after removal of tannins, were co-incubated in the presence or absence of the indicated LPS concentration. The lipid A-binding assays showed that Radix et Rhizoma Rhei, Caulis Sargentodoxae and PSA still possessed higher response units than that of others, and at more than 500 arc-sec. Furthermore, PSA showed the highest lipid A-binding ability among the 12 herbs (Table 1). So, we further investigated the anti-LPS ability of PSA using an affinity biosensor, polyamide chromatography and IEC–HPLC.

Lipid A-binding fractions from PSA

To determine which components of PSA could inhibit LPS, we isolated the aqueous extracts and tested their lipid A-binding abilities via polyamide chromatography and an affinity biosensor. As a result, four fractions were obtained from the aqueous extract of PSA (Figure 1a) and bound to lipid A which was immobilized on the surface of a non-derivatized cuvette. We found that the first fraction possessed the higher lipid A-binding activity compared with the other fractions, at more than 1800 RU (arc-sec) (Figure 1b).

To further study the bioactivities of the PSA-I fraction, PSA-I was passed on an IEC–HPLC system (SPFF 90 μ m). We collected three HPLC fractions (PSA1–3) (Figure 2a) and measured the lipid A-binding activity. Our results showed that the third fraction (PSA-I-3) bound more significantly to lipid A than other fractions, and at up to 550 arc-sec (Figure 2b). These results suggested that PSA-I-3 perhaps could be an inhibitor of LPS *in vitro* or *in vivo*.




Figure 4 LPS neutralization by PSA-I-3 *in vitro*

To determine whether PSA-I-3 could antagonize the bioactivity of LPS, we verified LPS neutralization of PSA-I-3 *in vitro* via a *Limulus* test. To this end, two concentrations of the PSA-I-3 (1 and 10 μ g/ml) were co-incubated in the presence or absence of LPS (10 ng) at 37 °C for 30 min. Control experiments were as follows: positive control (1 μ g PMB + 10 ng LPS); negative control, 10 ng LPS; and the internal control was sterile NS. Then 100 μ l of each mixture was added to LAL reagent of an equal volume. The kinetic turbidity was measured using an EDS-99 Tube Reader. The value of LPS was expressed as mean (EU/ml) $\pm$ S.D. A P -value < 0.05 (double-sided) was considered significant, and a P -value < 0.01 was considered as very significant. The test was carried out more than three times.

LPS neutralization and inhibition of TNF α release induced by LPS *in vitro* in RAW264.7 cells

To further evaluate the biological activities of PSA-I-3 against LPS *in vitro*, we measured its abilities to neutralize LPS and to inhibit TNF α release (by LPS challenge) in RAW264.7 cells. In agreement with our hypotheses, the results showed that PSA-I-3 significantly inhibited the LPS-induced RAW264.7 cells to release TNF α in a concentration-dependent manner compared with the negative control (10 ng LPS) ($P < 0.001$) (Figure 3). Beyond our expectation, however, PSA-I-3 could not inhibit the lysis of *Limulus* amoebocytes by LPS, it enhanced LAL instead (Figure 4), and the underlying mechanisms remain unclear.

Protection of PSA-I-3 on mice challenged by LPS and heat-killed *E. coli*

To further investigate the biological activities of PSA-I-3 against LPS *in vivo*, 40 mice (KM) were injected with PSA-I-3 (100 mg/kg) prior to a lethal challenge with LPS [18 mg/kg, i.v. (intravenously)]. The survival of mice was assessed at 6, 12, 24, 36, 48, 60, 72, 96 and 108 h, respectively. As a result, mice began to die 6 h after challenge with LPS, and the survival of mice with PMB and PSA-I-3 treatment were 80 and 50 % after 6 days,




Figure 5 Protection of PSA-I-3 on mice challenged by LPS

Forty mice (KM) were randomly divided into four groups (10 mice per group), mice (KM) were challenged with LPS (18 mg/kg) via the tail vein. Subsequently, PMB (2 mg/kg) and PSA-I-3 (100 mg/kg) were injected as the positive control and treatment groups by identical manners as stated above. PSA-I-3 (100 mg/kg) alone was the blank control. The survival of mice was assessed at 6, 12, 24, 36, 48, 60, 72, 96 and 108 h. Statistical comparisons of the survival between the experimental and control groups were made using the χ^2 test, and a P -value <0.01 was considered as very significant. The test was carried out no less than three times.

respectively. However, nine out of ten mice were dead by challenging with LPS alone approximately 1 week later. Our results suggest that PSA-I-3 protects mice significantly from challenge by a lethal-dose of LPS ($P < 0.005$) (Figure 5).

To determine whether PSA-I-3 also protected mice from challenge by natural LPS from *E. coli*, 100 mg/kg PSA-I-3 was administered followed by challenge with heat-killed *E. coli* (6.0×10^9 CFU/kg) via the tail vein. Post-challenge, the number of dead mice recorded was highest within 12 h and more than 60% of mice were killed in the non-treatment group, and none of the mice that survived died after 24 h in all of the groups. Compared with the non-treatment group, PSA-I-3 improved the survival of experimental animals but this did not show a significant difference (Figure 6).

DISCUSSION

Previously, we have reported the successful establishment of a platform to screen the active ingredients targeting CpG DNA from traditional Chinese herbs, and found an active component to bind with the platform. In the present study, we also used affinity biosensor technology to establish the platform to screen active ingredients from traditional Chinese herbs targeting lipid-A. It is a different target of LPS, and it was also confirmed that affinity biosensor technology is a rapid and effective method to screen the active fractions from traditional Chinese herbs.

The present study suggested that a lipid A-binding activity peptide possesses endotoxin-neutralizing molecules that could

have important clinical applications, which means that a high-binding affinity substance could neutralize endotoxin. However, we have to be sure that the substance is not toxic because it will serve as a treatment for sepsis. For example, PMB possesses high-affinity endotoxin binding, however, it also has severe side effects in humans [24]. Therefore we need to find a new compound with a high affinity to neutralize LPS, but with no toxicity.

PSA (Mudan Pi), belonging to the Paeoniaceae family, is an important traditional Chinese medicine used in many traditional prescriptions. An increasing number of studies showed that extracts of PSA possessed a large cohort of pharmacological functions such as anti-inflammation, anti-oxidation, anti-tumour and bacteriocidal functions [25–28]. However, the mechanisms behind the anti-inflammation effects are largely unknown owing to the absence of an effective tracking approach.

Tannins are water-soluble polyphenols, which present in many Chinese herbs and plant foods, which possess many bioactivities, such as antimicrobial, anticarcinogenic, antimutagenic, etc. In our previous experiments, we found that tannins from *Radix Paeoniae Rubra* bound greatly to lipid A and were anti-LPS *in vivo* and *in vitro*. However, this was restricted in clinical applications owing to a property of protein precipitation by intravenous administration. Herein, we first removed tannins of 12 Chinese herbs by adding excessive gelatine, and then co-incubated with the indicated LPS concentration. Finally, we tested the lipid A-binding abilities of each aqueous extraction. Our results demonstrated that the non-tannic aqueous extract from PSA bound greatly to lipid A after consumption with LPS. These findings suggest that PSA may possess abundant anti-LPS components among 12 Chinese herbs.




Figure 6 Protection of PSA-I-3 on mice challenged by heat-killed *E. coli*

Forty mice (KM) were randomly divided into four groups (10 mice per group) and were injected via the tail vein as follows: heat-inactivated *E. coli* (6.0×10^9 CFU/kg) alone as a negative control, and heat-inactivated *E. coli* (6.0×10^9 CFU/kg) adding dexamethasone (5 mg/kg) as the positive control. Heat-inactivated *E. coli* (6.0×10^9 CFU/kg) and immediate subsequent injection of PSA-I-3 (100 mg/kg) was the treatment group. PSA-I-3 (100 mg/kg) alone was a blank control. The general conditions and mice mortalities were assessed at 6, 12, 24, 36, 48, 60, 72, 96 and 108 h. Statistical comparisons of the survival between the experimental and control groups were made using the χ^2 test, and a P -value <0.01 was considered as very significant. The test was carried out no less than three times.

In order to investigate further the anti-LPS characteristics of PSA, we isolated the non-tannic aqueous extraction by affinity biosensor, polyamide chromatography and IEC-HPLC. Finally, we got a high-binding lipid A fraction from PSA (namely PSA-I-3) and tested the anti-sepsis activities *in vivo* and *in vitro*. Our results showed that PSA-I-3 could increase the survival of mice by lethal-dose LPS and heat-killed *E. coli* *in vivo* and inhibit significantly the TNF α release from LPS-stimulated RAW264.7 cells *in vitro*. However, PSA-I-3 could not arrest the lysis of *Limulus* amoebocytes by LPS. Instead, it enhanced LAL in spite of binding highly to lipid A. The underlying mechanism is unclear, but we think that it is perhaps related to the purity of PSA-3. In conclusion, our results showed that PSA-3 possessed a potential anti-sepsis ability, and it is necessary to further investigate its bioactivities in the future.

AUTHOR CONTRIBUTION

Yiguo Chen, Jie Yao, Nin Wang and Dongneng Jiang performed the research. Jiang Zheng designed the research. Jie Yao and Yiguo Chen wrote the paper.

FUNDING

This work was supported by the National Nature Scientific Foundation of China [grant numbers 81000225 and 81071537].

REFERENCES

- Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J. L. and Ramsay, G. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS Int. Sepsis Definitions Conf. Crit. Care Med. **31**, 1250–1256 [CrossRef PubMed](#)
- Minino, A., Heron, M., Murphy, S. and Kochanek, K. (2007) Deaths: final data for 2004. Natl Vital Stat. Rep. **55**, 1–120 [PubMed](#)
- Angus, D., Linde-Zwirble, W., Lidicker, J., Clermont, G., Carcillo, J. and Pinsky, M. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. **29**, 1303–1310 [CrossRef PubMed](#)
- Anname, D., Bellissant, E. and Cavaillon, J.-M. (2005) Septic shock. Lancet **365**, 63–78 [CrossRef PubMed](#)
- Chapman, S. J. R. and Iredell, J. R. (2008) Gram-negative sepsis in the intensive care unit: avoiding therapeutic failure. Curr. Opin. Infect. Dis. **21**, 604–609 [CrossRef PubMed](#)
- Kang, C. I., Kim, S. H., Park, W. B., Lee, K. D., Kim, H. B., Kim, E. C., Oh, M. D. and Choe, K. W. (2005) Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother. **49**, 760–766 [CrossRef PubMed](#)
- Rietschel, E. T., Kirikae, T., Schade, F. U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A. J., Zähringer, U., Seydel, U. and Di Padova, F. (1994) Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. **8**, 217–225 [PubMed](#)

- 8 Iwagaki, A., Porro, M. and Pollack, M. (2000) Influence of synthetic antiendotoxin peptides on lipopolysaccharide (LPS) recognition and LPS-induced proinflammatory cytokine responses by cells expressing membrane-bound CD14. *Infect. Immun.* **68**, 1655–1663 [CrossRef PubMed](#)
- 9 Vallespi, M. G., Alvarez-Obregón, J. C., Rodríguez-Alonso, I., Montero, T., Garay, H., Reyes, O. and Araña, M. J. (2003) A Limulus anti-LPS factor-derived peptide modulates cytokine gene expression and promotes resolution of bacterial acute infection in mice. *Int. Immunopharmacol.* **3**, 247–256 [CrossRef PubMed](#)
- 10 Ochia, M., Tamura, H., Yamamoto, A., Aizawa, M., Kataoka, M., Toyozumi, H. and Horiuchi, Y. (2002) A limulus amoebocyte lysate activating activity (LAL activity) that lacks biological activities of endotoxin found in biological products. *Microbiol. Immunol.* **46**, 527–533 [CrossRef PubMed](#)
- 11 Tsuzuki, H., Tani, T., Ueyama, H. and Kodama, M. (2001) Lipopolysaccharide: neutralization by polymyxin B shuts down the signaling pathway of nuclear factor κ B in peripheral blood mononuclear cell, even during activation. *J. Surg. Res.* **100**, 127–134 [CrossRef PubMed](#)
- 12 Derhaschnig, U., Reiter, R., Knöbl, P., Baumgartner, M., Keen, P. and Jilma, B. (2003) Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. *Blood* **102**, 2093–2098 [CrossRef PubMed](#)
- 13 Dunn, D. L., Priest, B. P. and Condie, R. M. (1988) Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. *Arch. Surg.* **123**, 1389–1393 [CrossRef PubMed](#)
- 14 Klaerner, H. G., Dahlberg, P. S., Acton, R. D., Battafarano, R. J., Uknis, M. E., Johnston, J. W. and Dunn, D. L. (1997) Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis. *J. Surg. Res.* **69**, 249–254 [CrossRef PubMed](#)
- 15 Jiang, Z., Hong, Z., Guo, W., Xiaoyun, G., Gengfa, L., Yongning, L. and Guangxia, X. (2004) A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin *in vitro* and *in vivo*. *Int. Immunopharmacol.* **4**, 527–537 [CrossRef PubMed](#)
- 16 Cross, A. S., Opal, S., Cooka, P., Drabick, J. and Bhattacharjee, A. (2004) Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis. *Vaccine* **22**, 812–817 [CrossRef PubMed](#)
- 17 Surolia, N. and Surolia, A. (2005) Polymyxin B: an ode to an old antidote for endotoxic shock. *Mol. Biosyst.* **1**, 213–222 [CrossRef PubMed](#)
- 18 Yibin, G., Jiang, Z., Hong, Z., Gengfa, L., Liangxi, W., Guo, W. and Yongling, L. (2005) A synthesized cationic tetradecapeptide from hornet venom kills bacteria and neutralizes lipopolysaccharide *in vivo* and *in vitro*. *Biochem. Pharmacol.* **70**, 209–219 [CrossRef PubMed](#)
- 19 Jiang, X. T., Liu, B. Y., Zhu, P. and Fu, N. (2009) Production and characterization of a cross-reactive monoclonal antibody to lipopolysaccharide. *Hybridoma (Larchmt)* **28**, 93–99 [CrossRef PubMed](#)
- 20 Wang, H., Xu, T. and Lewin, M. R. (2009) Future possibilities for the treatment of septic shock with herbal components. *Am. J. Emergency Med.* **27**, 107–111 [CrossRef](#)
- 21 Genfa, L., Jiang, Z., Hong, Z., Yimin, Z., Liangxi, W., Guo, W., Ming, H., Donglen, J. and Lizhao, W. (2005) The screening and isolation of an effective anti-endotoxin monomer from *Radix Paeoniae Rubra* using affinity biosensor technology. *Int. Immunopharmacol.* **5**, 1007–1017 [CrossRef PubMed](#)
- 22 Fu, J., Cao, H., Wang, N., Zheng, X., Lu, Y., Liu, X., Yang, D., Li, B., Zheng, J. and Zhou, H. (2008) An anti-sepsis monomer, 2',5,6',7-tetrahydroxyflavanonol (THF), identified from *Scutellaria baicalensis* Georgi neutralizes lipopolysaccharide *in vitro* and *in vivo*. *Int. Immunopharmacol.* **8**, 1652–1657 [CrossRef PubMed](#)
- 23 Yao, J., Zheng, J., Fu, W. and Zheng, J. (2009) Extraction of anti-sepsis component from *Terminalia chebula* Retz and evaluation of their biological activities. *Biosci. Rep.* **30**, 27–32 [CrossRef PubMed](#)
- 24 Ried, C., Wahl, C., Miethke, T. and Wellenhofer, G. (1996) High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant limulus anti-lipopolysaccharide factor. *Biol. Chem.* **271**, 28120–28127 [CrossRef](#)
- 25 Kim, S. H., Kim, S.-A., Park, M.-K., Kim, S.-H., Park, Y.-D., Na, H.-J., Kim, H.-M., Shin, M.-K. and Ahn, K.-S. (2004) Paeonol inhibits anaphylactic reaction by regulating histamine and TNF- α . *Int. Immunopharmacol.* **4**, 279–287 [CrossRef PubMed](#)
- 26 Oh, G. S., Pae, H. O., Choi, B. M., Jeong, S., Oh, H., Oh, C. S., Rho, Y. D., Kim, D. H., Shin, M. K. and Chung, H.-T. (2003) Inhibitory effects of the root cortex of *Paeonia suffruticosa* on interleukin-8 and macrophage chemoattractant protein-1 secretions in U937 cells. *J. Ethnopharmacol.* **84**, 85–89 [CrossRef PubMed](#)
- 27 Kang, D. G., Moon, M. K., Choi, D. H., Lee, J. K., Kwon, T. O. and Lee, H. S. (2005) Vasodilatory and anti-inflammatory effects of the 1,2,3,4,6- penta-O-galloyl- β -D-glucose (PGG) via a nitric oxide-cGMP pathway. *Eur. J. Pharmacol.* **524**, 111–119 [CrossRef PubMed](#)
- 28 Liu, F. and Ng, T. B. (2000) Antioxidative and free radical scavenging activities of selected medicinal herbs. *Life Sci.* **66**, 725–735 [CrossRef PubMed](#)

Received 30 October 2013/10 March 2014; accepted 14 March 2014

Published as Immediate Publication 24 March 2014, doi 10.1042/BSR20130103

Copyright of Bioscience Reports is the property of Portland Press Ltd. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.